At the news
? NEUTRALIMPACT 2/10 INSIDER-BUY filed Nov 6, 2026 at 06:39 ET
Director David R. Epstein purchased 15,000 shares of AgomAb Therapeutics for $104K in three open-market trades on November 5, 2026, with no 10b5-1 plan. The total value represents 0.03% of the company's $337M market cap, a trivial amount relative to company size.
- Director David R. Epstein bought 15,000 shares total in three open-market trades on November 5, 2026
- Total purchase value: $104K (0.03% of $337M market cap)
- All trades were open-market purchases (Form 4 code P) with no 10b5-1 plan
- Buyer is a Director, not C-suite (CEO/CFO)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access